Our research partnership with Florida State University College of Medicine and School of Biosciences addresses chronic disease management from a mechanistic, root-cause perspective. Chronic diseases currently drive over 90% of the $4.1 trillion in annual U.S. healthcare costs, with conventional pharmaceuticals often focusing on symptom relief rather than resolving the underlying causes. OG’s collaboration with FSU aims to change this paradigm with our novel, regenerative molecular therapeutics, offering a sustainable alternative to traditional treatments for pain, anxiety, and hypertension. With a proprietary approach incorporating cutting-edge genetic data, OG is crafting precision-targeted solutions that bypass common challenges such as off-target effects and addiction. The first product to be deployed in our development pipeline is anticipated as early as 2025, and is a revolutionary non-opioid pain management compound, which will be followed by  alternatives for anxiety and blood pressure management.